Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

ne year of angioplasty, and of heart failure and death following a heart attack. Prospective, randomized, clinical trials have demonstrated that the rate of heart attack in Hp2-2 diabetes can be decreased by the administration of natural vitamin E (400IU).

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical test to identify patients with Hp2-2 diabetes. This test, or a similar genetic form of the test, may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics'
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... 2015 Veracyte, Inc. (NASDAQ: VCYT ) ... and chief executive officer, will present at the Morgan ... at 10:30 a.m. ET in New York, ... webcast and subsequent replay may be accessed by visiting Veracyte,s website ... shortly after conclusion of the presentation and archived on ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... ... 02, 2015 , ... Advancing in medical imaging processing technology ... monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ZEUS all-in-one ... with simultaneous access to high precision medical images and electronic health records. ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... HONG KONG, Dec. 13, 2010 /PRNewswire-Asia-FirstCall/  - China Cord ... "the Company"), the first and largest cord blood banking ... previously announced warrant exchange offer, which allowed warrant holders ... outstanding.  The Company issued 1,627,518 ordinary shares, equivalent to ...
... people alive today can recount the extraordinary struggles that Drs. ... winner for Medicine or Physiology, confronted when they defied ... (IVF) in the 1970s. Now, Dr. Joseph D. Schulman, the ... Britain on the development of IVF, has written a new ...
... Dec. 13, 2010 BioTrends Research Group, Inc. ... oral disease-modifying agent (DMA) for the treatment of multiple sclerosis ... MS market. One month after the launch of Gilenya, trial ... year earlier, continues to be tempered due to the perception ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... , Hunted to near extinction, sea otters are ... reintroduction, however, is expected to reduce the numbers of ... as sea urchins and geoducks. Despite ... at the University of British Columbia, believes there is ...
... French . , For more than a decade, Peter ... up the production of stem cells and their descendants. The raw ... end products are blood and heart cells lots of them. ... To do this, he has been applying engineering principles to stem ...
... Images of dolphins and turtles ensnared in tuna nets ... on ocean bio-diversity. Known in fisheries science as by-catch, ... that has resisted easy answers. One possible solution, ... Fraser University (SFU) in British Columbia involves digital maps ...
Cached Biology News:From stem cells to organs: The bioengineering challenge 2New tool for resolving fisheries conflicts 2
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
Standard Fluka For microscopy (Hist.) redox indicator...
... a combination of an orbital shaker and ... while providing gentle, thorough mixing without foaming. ... used for a variety of applications including ... immunoblots, staining/destaining, chromatography, etc. The VSN-5 Nutating ...
... state-of-the-art software for all your biopharmaceutical applications ... a single, scalable software package. The graphical ... the control of all Freedom instruments from ... 100 with one liquid handling arm up ...
Biology Products: